|Articles|November 15, 2022
Utilizing Automated High-Throughput SEC Native Mass Spectrometry for mAb Screening
Author(s)Agilent Technologies
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Coya Raises $11.1 Million to Advance Immunomodulatory ALS Program
2
HHS Releases New Guidance on Lowering Prescription Drug Prices Through DTC Programs
3
AstraZeneca’s $15 Billion Investment Deepens China R&D and Manufacturing Footprint
4
Industrial-Scale Cell Therapy Automation Gains Traction with New Cellares Funding
5